09/22/2026
Today, we’re proud to announce $22M in Series A funding (bringing our total raised to $45M) led by .406 Ventures, with continued backing from Emerson Collective, Serena Ventures, Forerunner, Metrodora, and more.
This capital allows us to expand access to the Teal Wand—the first and most accurate FDA-authorized at-home HPV self-collection device for cervical cancer screening—paired with end-to-end telehealth care.
For too long, cervical cancer screening has meant painful speculums, long clinic wait times, and hard-to-find appointments. Nearly 1 in 3 women in the U.S. is behind on screening, not because they don’t prioritize their health, but because the traditional in-office experience makes it so difficult. Today is proof thay women, clinicians, and health systems are ready for an accurate, comfortable screening alternative.
This capital will fuel our next phase: expanding partnerships with employers, health systems, and payers to make at-home screening routine and accessible, preparing for broad insurance coverage in 2027.
To every woman who has trusted us with her care, ordered a kit, or finally checked screening off her to-do list after years of putting it off: this is for you. Thank you for building this movement with us.
We’ve achieved nationwide expansion, screened thousands of under screened women, earned a 4.95 star experience rating, and we’re just getting started!
